A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/13 (2006.01) A61K 31/11 (2006.01) A61K 31/135 (2006.01) A61K 31/137 (2006.01) A61K 45/06 (2006.01)
Patent
CA 2341441
Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive- compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites like desmethylsibutramine and didesmethylsibutramine and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3, antagonists.
On décrit des procédés permettant de traiter et de prévenir des dérèglements et des troubles comprenant, sans aucune limitation, la dysérection, les troubles affectifs, la prise de poids, les troubles de fonctionnement du cerveau, la douleur, les troubles névrotiques obsessionnels, l'abus de substances psychoactives, les troubles chroniques, l'anxiété, les troubles de l'alimentation, les migraines et l'incontinence. Les procédés consistent à administrer un inhibiteur de recaptage de la dopamine et facultativement un autre composé pharmaceutiquement actif. On décrit également des compositions pharmaceutiques et des formes posologiques qui contiennent un inhibiteur de recaptage de la dopamine et facultativement un autre composé pharmaceutiquement actif. Les inhibiteurs de recaptage de la dopamine préférés sont des métabolites de sibutramine racémiques ou optiquement purs et leurs sels, solvates et clathrates pharmaceutiquement acceptables. Les composés additionnels pharmaceutiquement actifs comprennent les substances médicamenteuses qui affectent le système nerveux central telles que les antagonistes 5-HT¿3?.
Fang Qun K.
Jerussi Thomas P.
Senanayake Chrisantha H.
Osler Hoskin & Harcourt Llp
Sepracor Inc.
LandOfFree
Methods of using and compositions comprising dopamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using and compositions comprising dopamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using and compositions comprising dopamine... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1841829